These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 14980127)

  • 41. Combined antiviral therapy for recurrent hepatitis C virus after liver transplantation.
    Fontana M; Ciuffreda D; Moradpour D; Pascual M
    Transplantation; 2007 Feb; 83(4):525-6. PubMed ID: 17318091
    [No Abstract]   [Full Text] [Related]  

  • 42. Genetic factors predicting response to interferon treatment for viral hepatitis C.
    Stärkel P
    Gut; 2008 Apr; 57(4):440-2. PubMed ID: 18334658
    [No Abstract]   [Full Text] [Related]  

  • 43. A randomized, double-blind, placebo-controlled dose-escalation trial of merimepodib (VX-497) and interferon-alpha in previously untreated patients with chronic hepatitis C.
    McHutchison JG; Shiffman ML; Cheung RC; Gordon SC; Wright TL; Pottage JC; McNair L; Ette E; Moseley S; Alam J
    Antivir Ther; 2005; 10(5):635-43. PubMed ID: 16152757
    [TBL] [Abstract][Full Text] [Related]  

  • 44. HCV-hepatocellular carcinoma: new findings and hope for effective treatment.
    Dash S; Haque S; Joshi V; Prabhu R; Hazari S; Fermin C; Garry R
    Microsc Res Tech; 2005 Nov; 68(3-4):130-48. PubMed ID: 16276514
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Incidence, risk factors, and outcome of chronic rejection during antiviral therapy for posttransplant recurrent hepatitis C.
    Fernández I; Ulloa E; Colina F; Abradelo M; Jiménez C; Gimeno A; Meneu JC; Lumbreras C; Solís-Herruzo JA; Moreno E
    Liver Transpl; 2009 Aug; 15(8):948-55. PubMed ID: 19642125
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Hepatitis C, interferon, and risk of rejection after liver transplantation.
    Samuel D
    Liver Transpl; 2004 Jul; 10(7):868-71. PubMed ID: 15237370
    [No Abstract]   [Full Text] [Related]  

  • 47. Review article: hepatitis C virus-associated steatosis--pathogenic mechanisms and clinical implications.
    Adinolfi LE; Durante-Mangoni E; Zampino R; Ruggiero G
    Aliment Pharmacol Ther; 2005 Nov; 22 Suppl 2():52-5. PubMed ID: 16225474
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The future of vaccines--cancer meets infectious diseases: cancer vaccines and emerging vaccines. 10-13 April 2003, Semmering, Austria.
    Ulmer JB
    IDrugs; 2003 Jun; 6(6):525-6. PubMed ID: 12861987
    [No Abstract]   [Full Text] [Related]  

  • 49. [Indications for serum albumin therapy].
    SOULIER JP
    Sem Hop; 1957 Jun; 33(36):2305-6. PubMed ID: 13454894
    [No Abstract]   [Full Text] [Related]  

  • 50. ESPGHAN 54th Annual Meeting Abstracts.
    J Pediatr Gastroenterol Nutr; 2022 Jun; 74(S2 Suppl 2):1-1172. PubMed ID: 35648390
    [No Abstract]   [Full Text] [Related]  

  • 51. 54th Annual Conference of Association of Microbiologists of India (AMI): A Report.
    Shukla P
    Indian J Microbiol; 2014 Jun; 54(2):244-5. PubMed ID: 25320431
    [No Abstract]   [Full Text] [Related]  

  • 52. 54th North American Chemical Residue Workshop.
    Sapozhnikova Y
    J Agric Food Chem; 2018 May; 66(20):4985. PubMed ID: 29683666
    [No Abstract]   [Full Text] [Related]  

  • 53. Viral kinetics in patients with chronic hepatitis C treated with the serine protease inhibitor BILN 2061.
    Herrmann E; Zeuzem S; Sarrazin C; Hinrichsen H; Benhamou Y; Manns MP; Reiser M; Reesink H; Calleja JL; Forns X; Steinmann GG; Nehmiz G
    Antivir Ther; 2006; 11(3):371-6. PubMed ID: 16759054
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Novel robust hepatitis C virus mouse efficacy model.
    Zhu Q; Oei Y; Mendel DB; Garrett EN; Patawaran MB; Hollenbach PW; Aukerman SL; Weiner AJ
    Antimicrob Agents Chemother; 2006 Oct; 50(10):3260-8. PubMed ID: 17005803
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Interferon-based therapy of hepatitis C.
    Chevaliez S; Pawlotsky JM
    Adv Drug Deliv Rev; 2007 Oct; 59(12):1222-41. PubMed ID: 17869375
    [TBL] [Abstract][Full Text] [Related]  

  • 56. New therapeutic options for hepatitis C.
    Waters L; Nelson M
    Curr Opin Infect Dis; 2006 Dec; 19(6):615-22. PubMed ID: 17075339
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Review of recent research on hepatitis C therapy for 54th annual meeting of the American association for the study of liver diseases].
    Wei L
    Zhonghua Gan Zang Bing Za Zhi; 2004 Feb; 12(2):118-20. PubMed ID: 14980127
    [No Abstract]   [Full Text] [Related]  

  • 58. Hepatitis C drug being developed.
    AIDS Patient Care STDS; 2004 Jan; 18(1):62. PubMed ID: 15080102
    [No Abstract]   [Full Text] [Related]  

  • 59.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.